Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$78.10M+885.45%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Casey Hoyt
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Employees
- 1,438
- Beta
- 1.09
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 6.13
Financials
Revenue
$78.10M+885.5%Net Income
$2.76M+612.4%EBITDA
$12.58M+1415.5%Free Cash Flow
$7.44M+111.7%EPS (diluted)
$0.07+8.2%Shares Outstanding (diluted)
41.13M+585.4%Operating Expenses
$39.67MCash & Debt
$10.68MReturn of Capital
$5.32MRevenue by Segment (annual)
$75.14MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $270.28M | $14.93M | $0.38 |
| 2024 | $224.26M | $11.27M | $0.29 |
| 2023 | $183.01M | $10.24M | $0.27 |
| 2022 | $138.83M | $6.22M | $0.15 |
| 2021 | $117.06M | $9.13M | $0.23 |
| 2020 | $131.31M | $31.53M | $0.86 |
| 2019 | $80.26M | $8.53M | $0.23 |
| 2018 | $64.46M | $9.51M | $0.25 |
| 2017 | $46.93M | $8.18M | $0.22 |
| 2016 | $31.36M | $1.23M | $0.03 |
| 2015 | $37.57M | $8.93M | $1.62 |
| 2014 | $23.29M | $9.45M | $1.58 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from VMD's reported EPS growth of -12.2% a year over 11 years.
- EPS in 5 years
- $0.20
- Implied price
- $4.01
- Return from $8.91
- -14.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $1.99 — -77.6% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 14 | 17 | 20 | 23 | 26 |
|---|---|---|---|---|---|
| -22.2% | -29.7% | -26.9% | -24.5% | -22.3% | -20.4% |
| -17.2% | -25.2% | -22.2% | -19.6% | -17.3% | -15.3% |
| -12.2% | -20.6% | -17.5% | -14.8% | -12.4% | -10.2% |
| -7.2% | -16.1% | -12.8% | -9.9% | -7.4% | -5.1% |
| -2.2% | -11.6% | -8.1% | -5.1% | -2.4% | 0.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (3)
- Newsnewsfilecorp.com·5h ago·Neutral
Viemed Healthcare, Inc. to Present at the 20th Annual LD Micro Main Event Lafayette, Louisiana--(Newsfile Corp. - October 6, 2026) - Viemed Healthcare, Inc. (NASDAQ: VMD) announced today that it will participate in the 20th Annual LD Micro Main Event, taking place October 19-21, 2026 at the Luxe Sunset Boulevard Hotel in Los Angeles, California. Viemed Healthcare, Inc. is scheduled to present on Tuesday, October 20, 2026 at 12:30 PM PT.
View source ↗ - Newsseekingalpha.com·8d ago·Neutral
Viemed Healthcare: Improving Capital Efficiency Creates A Strong Buy Opportunity Viemed Healthcare (VMD) is evolving from a capital-intensive respiratory equipment company into a diversified, capital-light home healthcare provider. VMD's expansion into sleep, resupply, and women's health segments is driving robust revenue growth while reducing capital intensity and supporting free cash flow acceleration. Despite margin compression from the new business mix, VMD needs only 0.5% annual free cash f…
View source ↗ - Newsmarketbeat.com·38d ago·Neutral
Viemed Healthcare Targets Low-20% Growth as Home Ventilation Opportunity Expands Viemed Healthcare NASDAQ: VMD outlined its growth strategy, product diversification and capital allocation priorities at the Midwest IDEAS Conference, emphasizing its focus on providing in-home care for patients with complex respiratory conditions.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $0.12 per share
Typical surprise -5.9% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 3$0.07 vs $0.12miss
- Tue, May 5$0.06 vs $0.09miss
- Wed, Mar 4$0.14 vs $0.12beat
- Wed, Nov 5$0.09 vs $0.09beat
- Wed, Aug 6$0.08 vs $0.09miss
- Wed, May 7$0.06 vs $0.06beat
Estimates and results for VMD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by VMD officers and directors.
- Bought
- —
- Sold
- $1.6m
0 trades
9 trades
- Frazier Williamsold
- Smokoff Timothysold
- Smokoff Timothysold
- Smokoff Timothysold
- Smokoff Timothysold
- Smokoff Timothysold
- Moore Michaelsold
- Moore Michaelsold
91 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in VMD.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.